These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 19149891)

  • 1. Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics.
    Zuluaga AF; Agudelo M; Rodriguez CA; Vesga O
    BMC Clin Pharmacol; 2009 Jan; 9():1. PubMed ID: 19149891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator.
    Vesga O; Agudelo M; Salazar BE; Rodriguez CA; Zuluaga AF
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3271-9. PubMed ID: 20547818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin.
    Rodriguez CA; Agudelo M; Zuluaga AF; Vesga O
    BMC Infect Dis; 2010 Jun; 10():153. PubMed ID: 20525378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic equivalence requires pharmaceutical, pharmacokinetic, and pharmacodynamic identities: true bioequivalence of a generic product of intravenous metronidazole.
    Agudelo M; Vesga O
    Antimicrob Agents Chemother; 2012 May; 56(5):2659-65. PubMed ID: 22330928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin.
    Agudelo M; Rodriguez CA; Zuluaga AF; Vesga O
    PLoS One; 2019; 14(2):e0211096. PubMed ID: 30726248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model.
    Zuluaga AF; Agudelo M; Cardeño JJ; Rodriguez CA; Vesga O
    PLoS One; 2010 May; 5(5):e10744. PubMed ID: 20505762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of various animal models of human infections to establish therapeutic equivalence of a generic product of piperacillin/tazobactam.
    Agudelo M; Rodriguez CA; Zuluaga AF; Vesga O
    Int J Antimicrob Agents; 2015 Feb; 45(2):161-7. PubMed ID: 25481459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro equivalence of generic and branded amoxicillin tablet by microbiological assay method.
    Avianto P; Mahfudz ; Suharjono ; Isnaeni ; Alderman CP
    J Basic Clin Physiol Pharmacol; 2020 Jan; 30(6):. PubMed ID: 31939272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Even apparently insignificant chemical deviations among bioequivalent generic antibiotics can lead to therapeutic nonequivalence: the case of meropenem.
    Agudelo M; Rodriguez CA; Pelaez CA; Vesga O
    Antimicrob Agents Chemother; 2014; 58(2):1005-18. PubMed ID: 24277034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro study of the antimicrobial activities of different commercial antibiotic products of vancomycin.
    Diaz JA; Silva E; Arias MJ; Garzón M
    BMC Clin Pharmacol; 2011 Jul; 11():9. PubMed ID: 21777438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics of nine generic products of amikacin compared with the innovator in the neutropenic mouse thigh infection model.
    Zuluaga AF; Rodriguez CA; Agudelo M; Vesga O
    BMC Res Notes; 2015 Oct; 8():546. PubMed ID: 26445936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam.
    Rodriguez CA; Agudelo M; Aguilar YA; Zuluaga AF; Vesga O
    PLoS One; 2016; 11(5):e0155806. PubMed ID: 27191163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Penetration of antibiotics through Staphylococcus aureus and Staphylococcus epidermidis biofilms.
    Singh R; Ray P; Das A; Sharma M
    J Antimicrob Chemother; 2010 Sep; 65(9):1955-8. PubMed ID: 20615927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact on resistance of the use of therapeutically equivalent generics: the case of ciprofloxacin.
    Rodriguez CA; Agudelo M; Zuluaga AF; Vesga O
    Antimicrob Agents Chemother; 2015 Jan; 59(1):53-8. PubMed ID: 25313208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbiological assay for gatifloxacin in pharmaceutical formulations.
    Salgado HR; Lopes CC; Lucchesi MB
    J Pharm Biomed Anal; 2006 Feb; 40(2):443-6. PubMed ID: 16139980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of In Vivo Pharmacokinetics and Pharmacodynamics of Vancomycin Products Available in Korea.
    Kim HK; Choi SM; Kang G; Park KH; Lee DG; Park WB; Rhee SJ; Lee S; Jung SI; Jang HC
    Yonsei Med J; 2020 Apr; 61(4):301-309. PubMed ID: 32233172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro inhibition of coagulase-negative staphylococci by vancomycin/aminoglycoside-loaded cement spacers.
    Streuli JC; Exner GU; Reize CL; Merkofer C; Scott CP; Zbinden R
    Infection; 2006 Apr; 34(2):81-6. PubMed ID: 16703297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating measurement uncertainty in the microbiological assay of vancomycin from methodology validation data.
    Lourenço FR; Kaneko TM; Pinto Tde J
    J AOAC Int; 2007; 90(5):1383-6. PubMed ID: 17955983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-substituted piperazinyl sarafloxacin derivatives: synthesis and in vitro antibacterial evaluation.
    Asadipour A; Moshafi MH; Khosravani L; Moghimi S; Amou E; Firoozpour L; Ilbeigi G; Beiki K; Soleimani E; Foroumadi A
    Daru; 2018 Dec; 26(2):199-207. PubMed ID: 30392156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microbiological assay for ceftazidime injection.
    De Haro Moreno A; Salgado HR
    J AOAC Int; 2007; 90(5):1379-82. PubMed ID: 17955982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.